Compare Riot Platforms Inc (RIOT) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Riot Platforms Inc vs Twist Bioscience Corp — how do they compare? Riot Platforms Inc trades at $16.92 (market cap $6.32B), while Twist Bioscience Corp trades at $162.88 (market cap $10.08B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Riot Platforms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Riot Platforms Inc for 16 Days and Twist Bioscience Corp for 27 Days on average.
| RIOT | TWST | |
|---|---|---|
Market Cap | $6.32B | $10.08B |
Volume | 30,571,756 | 4,229,037 |
Sector | Financials | Health |
52-Week High | $28.67 | $205.00 |
52-Week Low | $11.83 | $25.45 |
Typical Hold Time | 16 Days | 27 Days |
Enterprise Value | $6.73B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RIOT stock trades at $16.69, down 9.98% with bearish technical signals despite strong analyst support. The company shows concerning fundamentals with negative net income margins (-196.28%) and ROE (-48.24%), though revenue reached $647.44M in 2025. Recent strategic shift to data center services with $9.8B in contracted lease revenue through 2048 provides long-term visibility.
While analyst consensus remains strongly bullish (94.74% buy ratings) with $31.64 price target, execution risks persist given consecutive earnings misses and negative cash flow. The AI infrastructure pivot offers growth potential but requires careful monitoring of profitability improvements and Bitcoin market volatility exposure.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
